CRVS Options Alarm Sounds Ahead of November Earnings

Corvus Pharmaceuticals heads into its November 3 earnings report with options traders raising a sharp defensive flag, even as the stock bounces back from a bruising month.

The clearest signal this week is in the options market. The put/call ratio has climbed to 1.03, more than double its 20-day average of 0.45. That puts the current reading 2.5 standard deviations above the recent norm, near the 52-week high of 1.06 hit the prior session. Two weeks ago the ratio was sitting below 0.25. The shift from call-heavy to put-heavy positioning happened fast, and it coincides directly with the stock's approach to earnings.

Short interest adds another layer of caution, though the story there is more stable than extreme. Bears hold 23.4% of the free float short, a level that has barely moved over the past week (up just 0.25%). The more significant observation is the direction over a longer window: short positions peaked above 25% of float in mid-September and have been gradually unwinding since, falling roughly 8.7% over the past month. Borrow costs have followed the same path lower, now at 0.45%, down about 30% from where they were a month ago. Availability has loosened considerably too, with roughly 102% of short interest now available to borrow, compared to a trough near 55% in mid-September. The borrow market is not under stress, and there is no squeeze setup here, despite the elevated headline short figure.

The Street remains firmly constructive on the pipeline story, though analyst data is now several months old and should be read with that caveat. Seven buy-equivalent ratings are on record, with a mean price target well above the current price of $10.23. Goldman Sachs initiated coverage in April at Buy with a $40 target, and Jefferies carried a $42 target from January. Even the more conservative voices, Barclays at $28, Oppenheimer at $33, sit at multiples of where the stock trades today. The bull case centres on soquelitinib's Phase 1b/2 data in atopic dermatitis and the option value in expanding into other immune-mediated diseases. The bear case is a familiar one for clinical-stage biotechs: a single-asset dependency, high trial costs, and a competitive field that does not reward slow execution. EPS momentum factor scores rank in the 77th and 88th percentile over 30 and 90 days respectively, one of the stronger signals in the dataset. The short score, at 81.9, places CRVS in elevated short-positioning territory by ORTEX's composite measure, ranking in the 2nd percentile for its score rank, meaning few stocks carry heavier short positioning relative to their profile.

On ownership, two names on the 13D register are worth noting. OrbiMed Advisors filed a Schedule 13D/A, an activist designation, trimming its disclosed stake from 12.2% to 10.3% as of January 27. Adams Street Partners filed its own 13D/A in February. An activist 13D filing is a newsworthy fact: it signals an intention to engage with management rather than simply hold. OrbiMed remains the largest institutional holder with roughly 8.5% of shares by the most recent reported figures. BlackRock and State Street both added meaningfully in the September quarter, each buying close to 1 million shares. As always, 13D/G positions are event-driven disclosures around the 5% threshold; stakes are as last disclosed, and holders dropping below 5% may not file again. The stock's recent history around earnings is mixed but not particularly alarming: the August print produced a near-flat one-day move, though the five-day move that followed was a gain of nearly 9%.

With earnings thirteen days out, the question is whether the options-market caution is well-placed or a temporary crowding of protection buyers into the front month, with the stock's next trial update or financial disclosure the event that resolves it.